(4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• 化学式: C₁₁H₁₉NO₉
• 分子量: 309.27
• InChiKey: SQVRNKJHWKZAKO-USMSCUNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  177
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• [EN] PREPARATION OF SUGAR-NUCLEOTIDES<br/>[FR] PRÉPARATION DE SUCRES-NUCLÉOTIDES
  申请人：NOVO NORDISK AS

  公开号：WO2018115309A1

  公开（公告）日：2018-06-28

  The present invention relates to methods for preparation of glyco-conjugated proteins and in particular to processes for preparation of sugar-nucleotides and modified sugar-nucleotides.

  本发明涉及制备糖基结合蛋白质的方法，特别是制备糖核苷酸和修饰糖核苷酸的过程。
• ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF
  申请人：Tilos Theapeutics, Inc.

  公开号：EP3863722A2

  公开（公告）日：2021-08-18
• THERAPY FOR NEUROLOGICAL DISEASES/DISORDERS
  申请人：Akassoglou Katerina

  公开号：US20210330611A1

  公开（公告）日：2021-10-28

  Provided herein are compositions and methods to treat or prevent neurodegeneration in a mammal, inhibit microglial activation in the CNS of a mammal, promote survival of CNS neurons in a mammal, prevent or reduce the rate of demyelination and/or neuronal injury in a mammal, promote remyelination in a mammal and/or treat or prevent or decrease oxidative stress in a mammal.
• METHOD FOR THE PRODUCTION OF AMINO SUGAR CONTAINING PRODUCTS
  申请人：Universiteit Gent

  公开号：US20210355520A1

  公开（公告）日：2021-11-18

  A method or producing amino sugar (containing) products using metabolically engineered microorganisms is disclosed, wherein the conversion of UDP-N-acetylglucosamine to cell envelope precursors and molecules is reduced by altering the activity of enzymes involved in the synthesis of cell envelope precursors and molecules.
• [EN] ANTI-CD103 ANTIBODIES<br/>[FR] ANTICORPS ANTI-CD103
  申请人：ADURO BIOTECH HOLDINGS EUROPE B V

  公开号：WO2021219871A2

  公开（公告）日：2021-11-04

  The present invention relates to anti-CD103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases.